Feature

Five-year survival for non-Hodgkin lymphoma tops 71%


 

The overall 5-year survival rate for non-Hodgkin lymphoma (NHL) is 71.4%, according to the National Cancer Institute.

That number falls neatly into the middle of the range for survival by stage at diagnosis, with stage I (81.8%) and stage II (75.3%) disease on the high side and stage III (69.1%) and stage IV (61.7%) on the low side, the most recent data from the Surveillance, Epidemiology, and End Results (SEER) Program show. Five-year survival for NHL of unknown stage at diagnosis is 76.4%.

Non-Hodgkin lymphoma: 5-year survival by stage at diagnosis
The SEER data from 2008-2014 also show that the largest proportion of NHL cases at diagnosis is stage IV (34%), followed by stage I (25%), stage III (16%), stage II (14%), and unstaged (11%), the NCI said.

Recommended Reading

HIV-related lymphoma rate remains sky-high despite ART
MDedge Family Medicine
Cancer trends shifting in HIV-positive patients
MDedge Family Medicine
Hepatitis infection raises non-Hodgkin lymphoma risk in HIV patients
MDedge Family Medicine
Hodgkin lymphoma survival has nearly tripled since the 1950s
MDedge Family Medicine
Long view shows doubling of survival in non-Hodgkin lymphoma
MDedge Family Medicine
Neuropathic pain puts cancer survivors out of work
MDedge Family Medicine
Phase III trial: VZV protects auto-HCT patients
MDedge Family Medicine
Connective tissue diseases reported in patients receiving immune checkpoint inhibitors
MDedge Family Medicine
Solid organ transplantation contributes significantly to incidence of NHL among children and adolescents
MDedge Family Medicine
Decline in non-Hodgkin lymphoma deaths to continue in 2018
MDedge Family Medicine